ClinicalTrials.govpublic full text
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
metastatic hpv-16 positive squamous cell anal cancer, gene therapy, immunotherapy, cell therapy, adoptive cell therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 968753
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.